Abstract: An increasing incidence of osteonecrosis of the jaws (ONJ) in patients treated with intravenous bisphosphonates has been reported in the literature. The aim of this study was to evaluate the clinical aspects, diagnostic investigations, and management of ONJ...
Myeloma
Hyperbaric Oxygen Therapy (HBOT) Research for Myeloma.
Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma.
Abstract: A 60-year-old man with multiple myeloma (MM) (IgG-kappa, stage IIIA) had been treated with minodronate at 6 mg orally as a phase 1 clinical trial for myeloma bone disease for 13 months (total dose, 4032 mg). Then he received incadronate at 10mg intravenously...
New therapeutic protocol in the treatment of avascular necrosis of the jaws.
Abstract: Osteonecrosis of the jaws is being increasingly reported in patients with bone metastasis from a variety of solid tumors and disseminated multiple myeloma receiving intravenous bisphosphonates. Agreement exists that these drugs can initiate vascular...
Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series.
Abstract: Bisphosphonate (BP)-associated osteonecrosis of the jaw (ONJ) is an emerging problem with few therapeutic options. Our pilot study of BP-ONJ investigated a possible role for hyperbaric oxygen (HBO(2)) therapy. A total of 16 patients, ranging in age from 43...
Clinical experiences with bisphopsphonate induced osteochemonecrosis of the jaws.
Abstract: Bisphosphonates are frequently used drugs in the adjuvant therapy of bone metastases and tumour-induced hypercalcaemia, but also for osteoporosis or Pagets disease. Several publications within the last three years considered osteonecrosis of the jaws to be...
Bisphosphonate-associated osteonecrosis of the jaw: conclusions based on an analysis of case series.
Abstract: ONJ appears to be associated with BPs; however, the pathophysiology, incidence, and co-morbidities require further investigation. The major risk factors identified to date appear to be cancer (or chemotherapy for cancer) and dental procedures or oral trauma....
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
Abstract: Osteonecrosis of the jaw is an unremitting adverse outcome associated with bisphosphonate therapy in patients with multiple myeloma or bone metastases from solid tumors. Twelve patients who presented with exposed bone associated with bisphosphonates were...
Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.
Abstract: The current report presented 17 patients with cancer with bone metastases and 1 patient with osteopenia who received treatment with bisphosphonates and who subsequently developed osteonecrosis of the mandible and/or maxilla. The authors reviewed information...
Successful treatment of rhinocerebral zygomycosis using liposomal nystatin.
Abstract: We describe a case of successful treatment of rhinocerebral mucormycosis in a patient with multiple myeloma. Therapeutic strategies used included liposomal amphotericin, hyperbaric oxygen, GM-CSF and liposomal nystatin. Mileshkin, Slavin, Seymour, McKenzie,...